Company intelligence / Profile preview

New Aera

Cambridge/Boston area, Massachusetts, United Statesaera.net ↗

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Aera Therapeutics is developing proprietary protein nanoparticle and lipid nanoparticle platforms to address key challenges in delivering genetic medicines. Their technology, based on endogenous human proteins that self-assemble into capsid-like structures, aims to expand the reach of gene therapies beyond current limitations. The company also holds licenses for novel gene-editing enzymes but has not yet announced clinical results or programs in human trials.

Modalities: Small interfering RNAAntisense oligonucleotideMessenger RNA-based drugsDNA therapyGene therapyGene editing systems (including CRISPR-based therapy)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships have been publicly announced as of June 2025.

Beyond the preview

Go deeper on New Aera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Aera.

Explore the full profile